All In MedTech

Device Trial Radar · NCT03956563

Effect of Hybrid Laser 10600+1540 nm on GSM

Effect of Hybrid Laser 10600+1540 nm on Vaginal Atrophy-genitourinary Syndrome of the Menopause

Last checked: Nov 20, 2026Latest source record: May 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

30

Planned (sponsor's estimate)

Start

May 15, 2019

Primary completion

May 15, 2020

Study completion Aug 15, 2020

Sponsor

Lead sponsor
Quanta System, S.p.A.Not on our public-company list
Sponsor type
Industry
First posted
May 20, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Female only, from 45 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to clinically confirm, by comparison with a control group, the performance of the 10600 +1540 nm laser in the improvement of atrophic vaginal epithelium at 3 months after the last laser treatment. The secondary objectives are: 1. Confirm the performance of 10600 +1540 nm laser in the improvement of atrophic vaginal epithelium at 9 months post-laser treatment, and compare it with the results at 3 months. 2. Evaluate the improvement of the GSM urinary symptoms and urinary incontinence (UI) and their impact on the Quality of Life, at each timepoint after the first laser treatment. 3. To assess the Patient's Global Impression of Improvement (PGI) with the laser treatment * For the GSM symptoms * For the urinary symptoms and UI 4. To assess the patient's satisfaction with the laser treatment. * For the GSM symptoms * For the urinary symptoms and UI.

Conditions

  • Vaginal Atrophy
  • Genitourinary Disease

Interventions

  • Youlaser MT Group 2Device

    Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications. Each patient in the control arm will receive 3 simulated laser treatments every 30 days. A placebo consists in a sham device laser that simulates the acoustic signal even if it does not deliver any laser radiation to the subject.

  • Youlaser MT Group 1Device

    Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications. Each patient in the active arm will receive 3 laser treatments with the laser: one treatment administration every 30 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Atrophic vaginal epithelium changeTime frame: 3 months and 9 months post laser treatments

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Obstetrician & Gynecologist Hospital Universitario Sant Joan de Reus

    Reus, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.